Matrix Laboratories Limited

New Document

Financial Year 2007 - 2008

Quarter IV
(March 2008)

Quarter III
(December 2007)

Quarter II
(September 2007)

Quarter I
(June 2007)

Financial Year 2006 - 2007

Quarter IV
(March 2007)

Quarter III
(December 2006)

Quarter II
(September 2006)

Quarter I
(June 2006)
Financial Year 2005 - 2006

Quarter III
(December 2005)

Quarter II
(September 2005)

Quarter I
(June 2005)

Financial Year 2004 - 2005

Quarter IV
(March 2005)

Quarter III
(December 2004)

Quarter II
(September 2004)

Quarter I
(June 2004)

Financial Year 2003 - 2004

Quarter IV
(March 2004)

Quarter III
(December 2003)

Quarter II
(September 2003)

Quarter I
(June 2003)

Financial Year 2002 - 2003

Quarter IV
(March 2003)

Quarter III
(December 2002)

Quarter II
(September 2002)

Quarter I
(June 2002)

MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD - 500 003
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH JUNE 2005

(Rs.in Millions )
Sl.No	Particulars	Quarter ended 30th June		Year ended 31st March 2005 (Audited)
		2005 (Unaudited)	2004 (Unaudited)
01. 02. 03. 04. 05. 06. 07. 08. 09. 10. 11. 12. 13. 14. 15.	Sales (net) - Exports - Domestic Income from Potential patent infringment suit Other Income Total Expenditure a) (Increase) / Decrease in Stock b) Consumption of Raw materials c) Staff Cost d) Other Expenditure Profit Before R&D, Interest & Depreciation (1+2+3-4) Research and Development Expenditure Interest Depreciation Profit Before Tax (5-6-7-8) Provision for Tax - Current - Deferred - Fringe Benefit Profit After Tax (9-10) Equity Capital Reserves excluding revaluation reserves E.P.S (Face value-Rs.2/-) - Basic - Not Annualised - Annualised - Diluted - Not Annualised - Annualised Aggregate of Non promoters Shareholding Number of shares Face Value - Rs. Percentage of Shareholding	1543.37 705.32 838.05 66.91 111.27 1320.25 (23.83) 930.90 110.67 302.51 401.30 52.72 10.75 53.89 283.94 9.50 20.00 1.50 252.94 299.47 - 1.69 6.76 1.68 6.72 51904520 2/- 34.66%	1539.97 877.96 662.01 -- 25.60 1046.01 90.04 610.79 65.54 279.64 519.56 26.19 11.91 34.05 447.41 30 10 -- 407.41 145.54 -- 3.08 12.32 2.99 11.96 9135134 10/- 62.79%	6367.62 3409.62 2958.00 38.24 117.04 4499.84 (116.10) 3279.58 369.64 966.72 2023.06 159.35 62.77 191.00 1609.94 407.59 (100.32) -- 1302.67 299.42 6302.76 8.90 -- 8.87 -- 49907420 2/- 33.34%

Notes :

The above unaudited results were reviewed by the Audit Committee, considered and approved by the Board of Directors at their meeting held on 28th July 2005.
The figures for the corresponding quarter in the previous year pertain only to Matrix Laboratories Limited stand alone and to that extent is not comparable. Figures of the earlier period, have been regrouped to conform to those of the current quarter.
The activities of the Company relate to only one segment i.e. Pharmaceuticals.
The Company through its Belgian subsidiary - Matrix Laboratories NV, acquired controlling stake of approx. 22% (1,370,085 shares) at a price of Euro 34 per share aggregating to Euro 46.58 million (Rs.2436 million) in Docpharma NV, a Belgian based pharmaceutical company strong in marketing and distribution. The company intiated necessary steps for launching the public take-over of Docpharma's remaining shares listed on Euronext, Brussels at the same price.
Other income includes Rs.91 million being the Insurance claim towards loss of profits in relation to current quarter, consequent to fire accident in one of the manufacturing units in March 2005.
Provision fot tax has been estimated on prorata basis after considering various tax deductions available for the year ending 31st March 2006.
Summary of Investor Complaints

	For and on behalf of the Board
Place : Secunderabad Date : 28th July 2005	Sd/- N.PRASAD Executive Chairman

Foote Page